Navigation Links
Neurochem reports results for fourth quarter and fiscal year 2007 and important advances on corporate objectives
Date:2/20/2008

The MAA is being reviewed under the EMEA's centralized procedure. An authorization from the EMEA would apply to all 27 European Union member states, as well as Norway and Iceland.

The decrease in revenue from collaboration agreement for the current periods compared to the same periods in the previous year is mainly attributable to a change in the estimated period over which the non-refundable upfront payment received from Centocor in respect of eprodisate (KIACTA(TM)) is being amortized.

Reimbursable costs revenue amounted to $64,000 for the current quarter ($396,000 for the year), compared to $178,000 for the same period in the previous year ($712,000 for the year) and consists of costs reimbursable by Centocor in respect of eprodisate (KIACTA(TM))-related activities. The Company earns no margin on these reimbursable costs.

Research and development expenses, before research tax credits and grants, amounted to $12,199,000 for the current quarter ($55,732,000 for the year), compared to $14,142,000 for the same period in the previous year ($51,688,000 for the year). The decrease in the current quarter compared to the same period the previous year is mainly attributable to a reduction in expenses incurred in relation to the development of tramiprosate (ALZHEMED(TM)), primarily in respect of the North American Phase III clinical trial. Also, during the second quarter of 2007, the workforce was reduced due to delay encountered in the product candidate development programs. The increase in the current year compared to the same period the previous year is due to expenses incurred in relation to the development of tramiprosate (ALZHEMED(TM)), primarily in respect of the Phase III clinical trial in Europe and the North American open-label extension of the Phase III study, as well as the conduct of a QT cardiac status Phase I study. For the year ended December 31, 2007, research and development expenses also included costs incurred to support the North A
'/>"/>

SOURCE NEUROCHEM INC.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21

Related medicine news :

1. Neurochem to present at 2008 BIO CEO & Investor Conference - Presentation will be Web cast live
2. Neurochem appoints Mr. Gary Schmid as CEO of new nutraceutical business
3. Neurochem to present at JPMorgan Healthcare Conference
4. Neurochem announces European opinion for Eprodisate (KIACTA(TM)) for the treatment of AA amyloidosis
5. Neurochem announces eprodisate (KIACTA(TM)) receives acknowledgement of complete response and is granted Class 2 review
6. Neurochem announces departure of Dr. Philippe Calais, President, Global Business
7. Neurochem reports results for third quarter of fiscal 2007
8. Emageon Reports Fourth Quarter and 2007 Financial Results
9. Cyberonics Reports Operating Profit for Third Quarter FY08 and Announces Share Repurchase Program
10. Platinum Underwriters Holdings, Ltd. Reports Record Fourth Quarter and Year Ended December 31, 2007 Financial Results
11. Onyx Pharmaceuticals Reports Fourth Quarter and Twelve-Month 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2014)... announced today that will analyze how changes in ... contribute to healthy aging. , Conducted by ... a $10 million unrestricted gift from the Amway ... identify lifestyle and environmental factors that may help ... age. WELL will be designed, conducted, and analyzed ...
(Date:9/17/2014)... In its latest blog post, Best Drug ... family close by during a stay in rehab can make ... successful, is highlighting a member of the therapeutic care team ... addicts across the country and around the world: dogs. ... blood pressure, heart rate, and stress levels in recovering addicts,” ...
(Date:9/17/2014)... Bioluminescence, nanoparticles, gene manipulation these sound like ... in fact, they are components of an exciting ... In preclinical animal models of metastatic prostate cancer, ... VCU Institute of Molecular Medicine and Johns Hopkins ... molecular imaging approach that could revolutionize doctors, ability ...
(Date:9/17/2014)... In Pretrial Order #139 (Scheduling of ... conferences would be beneficial in this [MDL].” Accordingly, the ... the end of December,” the order further provides, “the ... conferences. , “The plain import of this order ... much to be discussed as these cases progress toward ...
(Date:9/17/2014)... HealthDay Reporter WEDNESDAY, Sept. 17, ... household chemicals known as phthalates might increase a child,s ... in a new study. Children had nearly an ... 5 and 11 if their mothers were exposed during ... the researchers found. The two phthalates were butylbenzyl phthalate ...
Breaking Medicine News(10 mins):Health News:First-ever research study examines impacts of diet and lifestyle on healthy aging 2Health News:Latest Best Drug Rehabilitation Blog Post Highlights How Dogs are Helping Addicts Recover 2Health News:New non-invasive technique could revolutionize the imaging of metastatic cancer 2Health News:New non-invasive technique could revolutionize the imaging of metastatic cancer 3Health News:Transvaginal Mesh Lawsuit News: New Order in C.R. Bard MDL Sets Schedule of Conferences for September to December, the Rottenstein Law Group LLP Reports 2Health News:Prenatal Exposure to Chemicals in Plastics Linked to Asthma Risk in Kids 2Health News:Prenatal Exposure to Chemicals in Plastics Linked to Asthma Risk in Kids 3Health News:Prenatal Exposure to Chemicals in Plastics Linked to Asthma Risk in Kids 4
... appears higher in non-Hispanic white adolescent girls and young ... in lower socioeconomic areas, according to a report posted ... issue of Archives of Dermatology , one of ... form of skin cancer and represents a substantial cause ...
... , MONDAY, March 21 (HealthDay News) -- A woman,s ... the risk of respiratory problems in her children, according to ... mother,s use of birth control pills may increase the risk ... inconclusive, said the authors of the new study. The ...
... (Mar. 21, 2011) -- A new study published by ... of California, Davis, foresees improvements in patient outcomes after ... technology. A control tower-style telemedicine hub to manage electronic ... boost the likelihood that critically injured victims will get ...
... less likely to refer short girls than short boys ... for their short stature, according to a new study ... medical conditions causing their short stature may go undiagnosed, ... treatment. Researchers from The Children,s Hospital of Philadelphia ...
... during pregnancy is common and is associated with significant ... Despite warnings from the Surgeon General to limit alcohol ... by the National Birth Defects Prevention Study(1) found that ... during their pregnancy, with one-fourth of the women surveyed ...
... Ellin Holohan HealthDay Reporter , SUNDAY, March 20 ... risk of developing diabetes and heart disease, according to a ... four other inflammatory conditions. The study, which looked at ... found higher rates of diabetes and heart illness among asthmatics ...
Cached Medicine News:Health News:Melanoma diagnosis in women associated with higher socioeconomic status 2Health News:Moms' Use of 'the Pill' Won't Raise Kids' Asthma Risk: Study 2Health News:Health information technology 'control tower' could improve earthquake response 2Health News:Medically underserved girls receive less frequent evaluation for short stature 2Health News:Medically underserved girls receive less frequent evaluation for short stature 3Health News:Adolescent offspring of women who drank alcohol during first trimester 2Health News:Study Ties Asthma to Higher Odds for Diabetes, Heart Disease 2Health News:Study Ties Asthma to Higher Odds for Diabetes, Heart Disease 3Health News:Study Ties Asthma to Higher Odds for Diabetes, Heart Disease 4
(Date:9/17/2014)... Sept. 17, 2014 Women everywhere know how ... not only uncomfortable, they,re often also embarrassing and have ... Feminine Health Support ( http://ph-defense.com ) is a new, ... an all-natural, homeopathic product. Odor, discharge, ... of vaginal infection. In many cases, the cause of ...
(Date:9/17/2014)... 2014  Aratana Therapeutics, Inc. (NASDAQ: ... licensing, developing and commercializing innovative biopharmaceutical products for ... public offering of 4,500,000 shares of its common stock at ... share. Aratana has granted the underwriters a 30-day ... shares of its common stock. Jefferies ...
(Date:9/17/2014)... , Sept. 17, 2014  Neuraltus Pharmaceuticals, Inc. announced ... 2 clinical program of NP001 for the treatment of ... disease) are being highlighted today in an oral presentation ... Group , being held in Bloomington, Minnesota ... hoc  analysis, administration of a high dose of NP001 ...
Breaking Medicine Technology:New Product from Vireo Systems: pH-D Feminine Health Support 2Aratana Therapeutics, Inc. Announces Pricing of Public Offering 2Neuraltus Pharmaceuticals' ALS Treatment Candidate, NP001, Highlighted at ALS Research Group Summit 2Neuraltus Pharmaceuticals' ALS Treatment Candidate, NP001, Highlighted at ALS Research Group Summit 3
... (ASH) Annual Meeting ... Publication Number: 840, ... thromboses (blood clots),and transfusion requirements in patients with a rare ... have,been expected to have less severe disease, according to data ...
... Mich., Dec. 10 CSG/SportsCoatings and,the National Wrestling ... the most proactive and proven method of controlling,bacteria, ... Nationally renowned for its Sports Antimicrobial System (R) ... on all types of,athletic surfaces and fabrics for ...
Cached Medicine Technology:PNH Patients With Lower Levels of Hemolysis, Mild Anemia and Minimal Transfusion Support Have Significant Disease Burden; Soliris(R) Therapy Provided Clinical Improvements in PNH Patients Regardless of Disease Severity 2PNH Patients With Lower Levels of Hemolysis, Mild Anemia and Minimal Transfusion Support Have Significant Disease Burden; Soliris(R) Therapy Provided Clinical Improvements in PNH Patients Regardless of Disease Severity 3PNH Patients With Lower Levels of Hemolysis, Mild Anemia and Minimal Transfusion Support Have Significant Disease Burden; Soliris(R) Therapy Provided Clinical Improvements in PNH Patients Regardless of Disease Severity 4PNH Patients With Lower Levels of Hemolysis, Mild Anemia and Minimal Transfusion Support Have Significant Disease Burden; Soliris(R) Therapy Provided Clinical Improvements in PNH Patients Regardless of Disease Severity 5PNH Patients With Lower Levels of Hemolysis, Mild Anemia and Minimal Transfusion Support Have Significant Disease Burden; Soliris(R) Therapy Provided Clinical Improvements in PNH Patients Regardless of Disease Severity 6PNH Patients With Lower Levels of Hemolysis, Mild Anemia and Minimal Transfusion Support Have Significant Disease Burden; Soliris(R) Therapy Provided Clinical Improvements in PNH Patients Regardless of Disease Severity 7PNH Patients With Lower Levels of Hemolysis, Mild Anemia and Minimal Transfusion Support Have Significant Disease Burden; Soliris(R) Therapy Provided Clinical Improvements in PNH Patients Regardless of Disease Severity 8National Wrestling Coaches Association Teams Up With CSG/SportsCoatings(TM) 2
18" Penrose drains...
Provides reliable suction for surgical cases with larger amounts of drainage....
Reliavac® 400cc kits with flat drain, Y-connector tubing...
Reliavac 100cc evacuators offer a more constant suction profile than silicone evacuators. 100cc capacity is easy for patient to carry. Bottom emptying port reduces chance of contamination....
Medicine Products: